New York, New York - Pfizer and BioNTech said that updated findings from the pivotal phase three trial of their Covid-19 vaccine supported safety and high efficacy in teens ages 12 to 15.

The updated data showed that a two-dose series of the Pfizer-BioNTech Covid-19 Vaccine was 100% effective, measured seven days through over four months after the second dose.

The companies noted that the data will support planned submissions for full regulatory approval of the vaccine in this age group in the US and worldwide.

The adverse event profile was generally consistent with other clinical safety data for the vaccine. No serious safety concerns were observed in individuals with at least six months of safety follow-up after the second dose, the companies said.

The vaccine is currently available for persons 12 through 15 years of age under Emergency Use Authorization, granted by the FDA in May 2021.

The companies also plan to submit these data to pursue regulatory approvals for this age group in other countries where emergency use authorizations or equivalents were initially granted.